Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Vertex Pharmaceuticals Stock News

VRTXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$493.84

1.370.28%

At close: -

$493.80

-0.04-0.01%

After Hours: Apr 25, 4:51 PM EDT

Q1 2025 Earnings in 9 days from now on Mon May 5th, after the market close

Vertex Pharmaceuticals (VRTX) Forecast

News

Earnings Vertex Pharmaceuticals (VRTX) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest Vertex Pharmaceuticals Stock News | NASDAQ:VRTX | Benzinga

Get the latest news on Vertex Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Vertex Pharmaceuticals performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, April 22, 2025

Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
Benzinga Insights - 4 days ago
Cantor Fitzgerald Assumes Vertex Pharmaceutic...
Benzinga Newsdesk - 4 days ago

Monday, April 21, 2025

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Surbhi Jain - 5 days ago

Thursday, April 17, 2025

Peering Into Vertex Pharmaceuticals's Recent Short Interest
Benzinga Insights - Apr 17, 2025, 9:00AM

Wednesday, April 16, 2025

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Vandana Singh - Apr 16, 2025, 4:06PM

Friday, April 11, 2025

CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
Avi Kapoor - Apr 11, 2025, 8:28AM

Thursday, April 10, 2025

UPDATE: CNBC Halftime Report Final Trades: Ve...
Benzinga Newsdesk - Apr 10, 2025, 1:03PM

Monday, April 07, 2025

These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?
Piero Cingari - Apr 7, 2025, 4:29PM
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Surbhi Jain - Apr 7, 2025, 12:11PM
'European Commission Approves Expanded Label ...
Benzinga Newsdesk - Apr 7, 2025, 12:09PM

Friday, April 04, 2025

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Vandana Singh - Apr 4, 2025, 4:22PM

Tuesday, April 01, 2025

Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Benzinga Insights - Apr 1, 2025, 1:45PM
RBC Capital Maintains Sector Perform on Verte...
Benzinga Newsdesk - Apr 1, 2025, 11:59AM

Monday, March 31, 2025

Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
Benzinga Insights - Mar 31, 2025, 6:00PM
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vandana Singh - Mar 31, 2025, 3:03PM
B of A Securities Maintains Buy on Vertex Pha...
Benzinga Newsdesk - Mar 31, 2025, 7:55AM

Friday, March 28, 2025

Vertex Announces Program Updates For Type 1 D...
Benzinga Newsdesk - Mar 28, 2025, 4:13PM
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Avi Kapoor - Mar 28, 2025, 8:27AM

Thursday, March 27, 2025

CNBC Halftime Report Final Trades: Vertex Pha...
Benzinga Newsdesk - Mar 27, 2025, 1:02PM

Friday, March 21, 2025

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Benzinga Insights - Mar 21, 2025, 11:15AM

Thursday, March 13, 2025

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Benzinga Insights - Mar 13, 2025, 4:00PM
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Benzinga Insights - Mar 13, 2025, 3:15PM

Wednesday, March 12, 2025

CNBC Halftime Report Final Trades: Netflix, M...
Benzinga Newsdesk - Mar 12, 2025, 1:03PM

Tuesday, March 11, 2025

CNBC Halftime Report Final Trades: Netflix, M...
Benzinga Newsdesk - Mar 11, 2025, 1:01PM
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Avi Kapoor - Mar 11, 2025, 8:55AM

Friday, March 07, 2025

Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vandana Singh - Mar 7, 2025, 12:37PM

Thursday, March 06, 2025

Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?
Maureen Meehan - Mar 6, 2025, 12:29PM

Thursday, February 27, 2025

Live On CNBC, Rob Sechan Announces Sold Verte...
Benzinga Newsdesk - Feb 27, 2025, 12:33PM

Wednesday, February 26, 2025

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights - Feb 26, 2025, 12:35PM

Tuesday, February 25, 2025

Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Benzinga Insights - Feb 25, 2025, 12:15PM

Monday, February 24, 2025

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Benzinga Insights - Feb 24, 2025, 3:00PM

Thursday, February 20, 2025

Analyst Expectations For Vertex Pharmaceuticals's Future
Benzinga Insights - Feb 20, 2025, 4:00PM
RBC Capital Maintains Sector Perform on Verte...
Benzinga Newsdesk - Feb 20, 2025, 11:50AM

Wednesday, February 12, 2025

This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Avi Kapoor - Feb 12, 2025, 9:02AM
Canaccord Genuity Upgrades Vertex Pharmaceuti...
Benzinga Newsdesk - Feb 12, 2025, 8:23AM

Tuesday, February 11, 2025

Truist Securities Maintains Buy on Vertex Pha...
Benzinga Newsdesk - Feb 11, 2025, 12:38PM
RBC Capital Maintains Sector Perform on Verte...
Benzinga Newsdesk - Feb 11, 2025, 12:17PM
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
Avi Kapoor - Feb 11, 2025, 9:55AM
Scotiabank Maintains Sector Perform on Vertex...
Benzinga Newsdesk - Feb 11, 2025, 9:55AM
Cantor Fitzgerald Reiterates Overweight on Ve...
Benzinga Newsdesk - Feb 11, 2025, 9:55AM
Barclays Maintains Equal-Weight on Vertex Pha...
Benzinga Newsdesk - Feb 11, 2025, 9:41AM
HC Wainwright & Co. Reiterates Buy on Vertex ...
Benzinga Newsdesk - Feb 11, 2025, 7:56AM
Morgan Stanley Maintains Equal-Weight on Vert...
Benzinga Newsdesk - Feb 11, 2025, 7:31AM
Needham Reiterates Hold on Vertex Pharmaceuti...
Benzinga Newsdesk - Feb 11, 2025, 7:04AM

Monday, February 10, 2025

Vertex COO Stuart Arbuckle To Retire Jul. 202...
Benzinga Newsdesk - Feb 10, 2025, 4:21PM
Vertex Pharmaceuticals Sees FY25 Revenue $11....
Benzinga Newsdesk - Feb 10, 2025, 4:02PM
Vertex Pharmaceuticals Q4 2024 Adj. EPS $3.98...
Benzinga Newsdesk - Feb 10, 2025, 4:02PM
Vertex Pharmaceuticals Q4 2024 GAAP EPS $3.50...
Benzinga Newsdesk - Feb 10, 2025, 4:01PM
Live On CNBC, Amy Raskin Announces Trimmed Ve...
Benzinga Newsdesk - Feb 10, 2025, 12:44PM
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Surbhi Jain - Feb 10, 2025, 10:20AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved